JP2017531693A - １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン - Google Patents

１種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン Download PDF

Info

Publication number
JP2017531693A
JP2017531693A JP2017538177A JP2017538177A JP2017531693A JP 2017531693 A JP2017531693 A JP 2017531693A JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017531693 A JP2017531693 A JP 2017531693A
Authority
JP
Japan
Prior art keywords
vaccine
antigen
seq
population
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017538177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531693A5 (enExample
Inventor
エリック ブラエニング
エリック ブラエニング
クラウス フリュー
クラウス フリュー
ルイス ピッカー
ルイス ピッカー
ベット ティー．エム． ケルバー
ベット ティー．エム． ケルバー
ジェイムズ タイラー
ジェイムズ タイラー
エミリー マーシャル
エミリー マーシャル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of JP2017531693A publication Critical patent/JP2017531693A/ja
Publication of JP2017531693A5 publication Critical patent/JP2017531693A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017538177A 2014-10-03 2015-10-05 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン Pending JP2017531693A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462059497P 2014-10-03 2014-10-03
US201462059506P 2014-10-03 2014-10-03
US62/059,506 2014-10-03
US62/059,497 2014-10-03
PCT/US2015/054067 WO2016054654A1 (en) 2014-10-03 2015-10-05 Hiv vaccines comprising one or more population episensus antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020170852A Division JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Publications (2)

Publication Number Publication Date
JP2017531693A true JP2017531693A (ja) 2017-10-26
JP2017531693A5 JP2017531693A5 (enExample) 2018-11-15

Family

ID=55631703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017538177A Pending JP2017531693A (ja) 2014-10-03 2015-10-05 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2020170852A Active JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2023003194A Active JP7441340B2 (ja) 2014-10-03 2023-01-12 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020170852A Active JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2023003194A Active JP7441340B2 (ja) 2014-10-03 2023-01-12 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Country Status (16)

Country Link
US (3) US10894078B2 (enExample)
EP (1) EP3200878B1 (enExample)
JP (3) JP2017531693A (enExample)
KR (1) KR102633096B1 (enExample)
CN (1) CN108064181A (enExample)
AU (2) AU2015327797A1 (enExample)
CA (1) CA2963573C (enExample)
EA (1) EA201790680A1 (enExample)
HK (1) HK1254806A1 (enExample)
IL (1) IL251469B2 (enExample)
MA (1) MA40783A (enExample)
MX (3) MX391149B (enExample)
SG (1) SG11201702729YA (enExample)
UA (1) UA126890C2 (enExample)
WO (1) WO2016054654A1 (enExample)
ZA (1) ZA202206809B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504298A (ja) * 2021-01-14 2024-01-31 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
WO2018009246A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
WO2020243485A1 (en) * 2019-05-29 2020-12-03 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
JP7454645B2 (ja) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン並びにその作製方法及び使用方法
PH12022550490A1 (en) 2019-08-29 2023-02-06 Triad Nat Security Llc Hepatitis b virus vaccines
US20240384296A1 (en) 2021-08-31 2024-11-21 Vir Biotechnology, Inc. Recombinant hcmv vectors and uses thereof
TW202436326A (zh) * 2023-02-13 2024-09-16 長怡 王 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
CN116524994A (zh) * 2023-02-20 2023-08-01 中国科学院天津工业生物技术研究所 一种基于贪婪算法的菌株构建排程设计方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
WO2014138209A1 (en) * 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
BR0212619A (pt) 2001-09-20 2004-08-17 Glaxo Group Ltd Sequência de nucleotìdeo, vetor, proteìna, composição farmacêutica, dispositivo de liberação intradérmica, método para tratar um paciente que sofre de uma doença ou é suscetìvel a ela, uso de uma sequência de nucleotìdeo, e, processo para a produção de um nucleotìdeo
AUPR842501A0 (en) * 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
EP1609107A4 (en) * 2003-03-28 2006-08-30 Idm Pharma Inc METHOD FOR IDENTIFYING OPTIMAL PEPTIDE PITOPARIANTS
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
AU2011203095A1 (en) 2003-09-17 2011-07-21 Duke University Consensus/Ancestral Immunogens
NZ547042A (en) 2003-10-10 2010-05-28 Powderject Vaccines Inc Method for eliciting a T-cell response
EP1766096B1 (en) 2004-05-25 2013-01-02 Oregon Health and Science University Hiv vaccination usingand hcmv-based vaccine vectors
WO2007024941A2 (en) * 2005-08-23 2007-03-01 The Regents Of The University Of California Polyvalent vaccine
KR102511874B1 (ko) 2006-07-28 2023-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
US20100183651A1 (en) * 2007-03-30 2010-07-22 Finnefrock Adam C Broadly Representative Antigen Sequences and Method for Selection
SMT201800631T1 (it) 2008-11-18 2019-01-11 Beth Israel Deaconess Medical Ct Inc Vaccini antivirali con immunogenicità cellulare migliorata
KR20120093941A (ko) * 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2011143653A2 (en) 2010-05-14 2011-11-17 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
US8557787B2 (en) 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
ES2718899T3 (es) 2012-03-02 2019-07-05 Us Gov Health & Human Services Método para modificar la jerarquía de inmunodominio de gag del VIH mediante una vacuna de ADN que expresa regiones conservadas
EP2983686B1 (en) * 2013-01-07 2024-05-29 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CA2941116A1 (en) 2014-02-28 2015-09-03 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
AU2015289560B2 (en) 2014-07-16 2018-09-27 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
EA202092521A1 (ru) 2014-09-26 2021-05-31 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
TWI792091B (zh) 2015-12-15 2023-02-11 荷蘭商傑森疫苗防護公司 人類免疫缺陷病毒抗原、載體、組成物、及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
WO2014138209A1 (en) * 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Protein Nef", UNIPROT, JPN6019030766, 19 October 2011 (2011-10-19), ISSN: 0004280750 *
BAROUCH DAN H. ET AL., NATURE MEDICINE, vol. 16, no. 3, JPN6019030770, March 2010 (2010-03-01), pages 319 - 323, ISSN: 0004092236 *
KORBER, BETTE T. M: "LANL/NEW MEXICO CONSORTIUM HIV VACCINE DESIGN AND ANALYSIS", [ONLINE], JPN5017008659, 7 July 2014 (2014-07-07), pages 10, ISSN: 0004092234 *
NOVITSKY V. ET AL., JOURNAL OF VIROLOGY, vol. 76, no. 11, JPN6019030767, June 2002 (2002-06-01), pages 5435 - 5451, ISSN: 0004280751 *
SANTRA SAMPA ET AL., NATURE MEDICINE, vol. 16, no. 3, JPN6019030768, 21 February 2010 (2010-02-21), pages 324 - 329, ISSN: 0004092235 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504298A (ja) * 2021-01-14 2024-01-31 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
JP2024177497A (ja) * 2021-01-14 2024-12-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
JP7693813B2 (ja) 2021-01-14 2025-06-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法

Also Published As

Publication number Publication date
KR20170122711A (ko) 2017-11-06
US20210046175A1 (en) 2021-02-18
MA40783A (fr) 2017-08-08
JP7441340B2 (ja) 2024-03-06
US10894078B2 (en) 2021-01-19
WO2016054654A1 (en) 2016-04-07
IL251469A0 (en) 2017-05-29
AU2021218141A1 (en) 2021-09-09
NZ731173A (en) 2024-04-26
SG11201702729YA (en) 2017-04-27
IL251469B1 (en) 2023-01-01
EP3200878B1 (en) 2025-06-04
US11554168B2 (en) 2023-01-17
IL251469B2 (en) 2023-05-01
EP3200878A4 (en) 2018-05-30
BR112017006865A2 (pt) 2017-12-12
MX2017004275A (es) 2018-01-17
UA126890C2 (uk) 2023-02-22
CN108064181A (zh) 2018-05-22
AU2021218141B2 (en) 2024-06-06
EA201790680A1 (ru) 2017-11-30
US11628215B2 (en) 2023-04-18
AU2015327797A1 (en) 2017-05-11
HK1254806A1 (zh) 2019-07-26
MX2022003663A (es) 2022-04-25
CA2963573A1 (en) 2016-04-07
JP7212020B2 (ja) 2023-01-24
JP2023059272A (ja) 2023-04-26
US20170319679A1 (en) 2017-11-09
JP2021035946A (ja) 2021-03-04
ZA202206809B (en) 2023-11-29
US20210046174A1 (en) 2021-02-18
KR102633096B1 (ko) 2024-02-02
MX391149B (es) 2025-03-21
MX2022003664A (es) 2022-04-25
EP3200878A1 (en) 2017-08-09
CA2963573C (en) 2024-02-06

Similar Documents

Publication Publication Date Title
JP7441340B2 (ja) １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
Rademeyer et al. Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization
Sok et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice
Ondondo et al. Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection
Kulkarni et al. HIV-1 p24gag derived conserved element DNA vaccine increases the breadth of immune response in mice
Rolland et al. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins
AU2024201392A1 (en) HIV immunotherapy with no pre-immunization step
JP2022101658A (ja) Ｈｉｖワクチン接種および免疫療法
CN113186223A (zh) 一种新冠病毒疫苗的表达载体及其构建方法、应用和疫苗
US20050221285A1 (en) Method for identifying or screening anti-viral agents
Lu et al. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice
CN114729010B (zh) 乙型肝炎病毒疫苗
Sarkar et al. Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope
HK1241309A1 (en) Hiv vaccines comprising one or more population episensus antigens
HK1241309B (en) Hiv vaccines comprising one or more population episensus antigens
EA040402B1 (ru) Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) антигенов для популяции
BR122021016789B1 (pt) Vacinas contra hiv-1 compreendendo um ou mais antígenos epissenso de população, usos das mesmas para proteger um indivíduo de uma infecção por hiv-1, tratar hiv-1 e induzir uma resposta de células t de memória efetoras, bem como polipeptídeo e método para projetar e produzir as ditas vacinas
D’Ursi et al. Molecular Mechanisms Involved in the B Cell Growth and Clonogenic Activity of HIV-1 Matrix Protein p17 Variants
BR112017006865B1 (pt) Vacina contra hiv-1 compreendendo um ou mais antígenos epissenso de população, uso da mesma para proteger um indivíduo de uma infecção por hiv-1 ou para tratar hiv-1 e polipeptídeo
HK40074198A (en) Hepatitis b virus vaccines
Meng et al. A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine
Darton et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B. 1.1. 7)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200610